Patents by Inventor Woonza M. Rhee
Woonza M. Rhee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210228764Abstract: The present invention provides a hemostatic composite sponge comprising oxidized cellulose and an essentially gelatin-free bioadhesive material stably associated with said sponge and present in an organized pattern on said sponge.Type: ApplicationFiled: April 15, 2021Publication date: July 29, 2021Inventors: Hans Christian Hedrich, Joris Hoefinghoff, Woonza M. Rhee, Atsushi Edward Osawa
-
Patent number: 11071804Abstract: The present invention provides a hemostatic composite sponge comprising oxidized cellulose and an essentially gelatin-free bioadhesive material stably associated with said sponge and present in an organized pattern on said sponge.Type: GrantFiled: December 15, 2017Date of Patent: July 27, 2021Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Hans Christian Hedrich, Joris Hoefinghoff, Woonza M. Rhee, Atsushi Edward Osawa
-
Publication number: 20180104377Abstract: The present invention provides a hemostatic composite sponge comprising oxidized cellulose and an essentially gelatin-free bioadhesive material stably associated with said sponge and present in an organized pattern on said sponge.Type: ApplicationFiled: December 15, 2017Publication date: April 19, 2018Inventors: Hans Christian Hedrich, Joris Hoefinghoff, Woonza M. Rhee, Atsushi Edward Osawa
-
Patent number: 9872934Abstract: The present invention provides a hemostatic composite sponge comprising a porous matrix of a biomaterial and a bioadhesive material stably associated with said sponge and present in an organized pattern on said sponge.Type: GrantFiled: December 1, 2016Date of Patent: January 23, 2018Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Hans Christian Hedrich, Joris Hoefinghoff, Woonza M. Rhee, Atsushi Edward Osawa
-
Publication number: 20170080119Abstract: The present invention provides a hemostatic composite sponge comprising a porous matrix of a biomaterial and a bioadhesive material stably associated with said sponge and present in an organized pattern on said sponge.Type: ApplicationFiled: December 1, 2016Publication date: March 23, 2017Inventors: Hans Christian Hedrich, Joris Hoefinghoff, Woonza M. Rhee, Atsushi Edward Osawa
-
Patent number: 9517287Abstract: The present invention provides a hemostatic composite sponge comprising a porous matrix of a biomaterial and a material enhancing the adherence of said sponge to the applied tissue stably associated with at least one surface of said sponge, a method of producing these sponges and their use in hemostasis.Type: GrantFiled: June 30, 2014Date of Patent: December 13, 2016Assignees: Baxter International, Inc., Baxter Healthcare, S.A.Inventors: Hans Christian Hedrich, Joris Hoefinghoff, Woonza M. Rhee, Atsushi Edward Osawa
-
Patent number: 9114172Abstract: Compositions, methods, and kits are provided for sealing applications. Compositions are prepared by combining a first cross-linkable component with a second cross-linkable component to form a porous matrix having interstices, and combining the porous matrix with a hydrogel-forming component to fill at least some of the interstices. The compositions exhibit minimal swelling properties.Type: GrantFiled: February 28, 2013Date of Patent: August 25, 2015Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Woonza M. Rhee, Cary J. Reich, A. Edward Osawa, Felix Vega
-
Patent number: 8962025Abstract: Compositions, methods, and kits are provided for sealing applications. Compositions are prepared by combining a first cross-linkable component with a second cross-linkable component to form a porous matrix having interstices, and combining the porous matrix with a hydrogel-forming component to fill at least some of the interstices. The compositions exhibit minimal swelling properties.Type: GrantFiled: August 1, 2007Date of Patent: February 24, 2015Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Woonza M. Rhee, Cary J. Reich, A. Edward Osawa, Felix Vega
-
Publication number: 20140378928Abstract: The present invention provides a hemostatic composite sponge comprising a porous matrix of a biomaterial and a material enhancing the adherence of said sponge to the applied tissue stably associated with at least one surface of said sponge, a method of producing these sponges and their use in hemostasis.Type: ApplicationFiled: June 30, 2014Publication date: December 25, 2014Inventors: Hans Christian Hedrich, Joris Hoefinghoff, Woonza M. Rhee, Atsushi Edward Osawa
-
Patent number: 8771258Abstract: The present invention provides a hemostatic composite sponge comprising a porous matrix of a biomaterial and a material enhancing the adherence of said sponge to the applied tissue stably associated with at least one surface of said sponge, a method of producing these sponges and their use in hemostasis.Type: GrantFiled: December 16, 2010Date of Patent: July 8, 2014Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Hans Christian Hedrich, Joris Hoefinghoff, Woonza M. Rhee, Atsushi Edward Osawa
-
Publication number: 20120207813Abstract: Compositions, methods, and kits are provided for sealing applications. Compositions are prepared by combining a first cross-linkable component with a second cross-linkable component to form a porous matrix having interstices, and combining the porous matrix with a hydrogel-forming component to fill at least some of the interstices. The compositions exhibit minimal swelling properties.Type: ApplicationFiled: April 26, 2012Publication date: August 16, 2012Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: Woonza M. RHEE, Cary J. REICH, A. Edward OSAWA, Felix VEGA
-
Patent number: 8197802Abstract: Provided are crosslinked polymer compositions that include a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple electrophilic groups. The first synthetic polymer is preferably a synthetic polypeptide or a polyethylene glycol that has been modified to contain multiple nucleophilic groups, such as primary amino (—NH2) or thiol (—SH) groups. The second synthetic polymer may be a hydrophilic or hydrophobic synthetic polymer, which contains or has been derivatized to contain, two or more electrophilic groups, such as succinimidyl groups. The compositions may further include other components, such as naturally occurring polysaccharides or proteins (such as glycosaminoglycans or collagen) and/or biologically active agents.Type: GrantFiled: December 28, 2010Date of Patent: June 12, 2012Assignee: AngioDevice International GmbHInventors: Woonza M. Rhee, Frank A. DeLustro, Richard A. Berg
-
Publication number: 20110202026Abstract: The present invention provides a hemostatic composite sponge comprising a porous matrix of a biomaterial and a material enhancing the adherence of said sponge to the applied tissue stably associated with at least one surface of said sponge, a method of producing these sponges and their use in hemostasis.Type: ApplicationFiled: December 16, 2010Publication date: August 18, 2011Applicants: Baxter International Inc., Baxter Healthcare S.A.Inventors: Hans Christian Hedrich, Joris Hoefinghoff, Woonza M. Rhee, Atsushi Edward Osawa
-
Publication number: 20110195040Abstract: Provided are crosslinked polymer compositions that include a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple electrophilic groups. The first synthetic polymer is preferably a synthetic polypeptide or a polyethylene glycol that has been modified to contain multiple nucleophilic groups, such as primary amino (—NH2) or thiol (—SH) groups. The second synthetic polymer may be a hydrophilic or hydrophobic synthetic polymer, which contains or has been derivatized to contain, two or more electrophilic groups, such as succinimidyl groups. The compositions may further include other components, such as naturally occurring polysaccharides or proteins (such as glycosaminoglycans or collagen) and/or biologically active agents.Type: ApplicationFiled: December 28, 2010Publication date: August 11, 2011Applicant: ANGIODEVICE INTERNATIONAL GMBHInventors: Woonza M. Rhee, Frank A. DeLustro, Richard A. Berg
-
Patent number: 7883694Abstract: Provided are crosslinked polymer compositions that include a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple electrophilic groups. The first synthetic polymer is preferably a synthetic polypeptide or a polyethylene glycol that has been modified to contain multiple nucleophilic groups, such as primary amino (—NH2) or thiol (—SH) groups. The second synthetic polymer may be a hydrophilic or hydrophobic synthetic polymer, which contains or has been derivatized to contain, two or more electrophilic groups, such as succinimidyl groups. The compositions may further include other components, such as naturally occurring polysaccharides or proteins (such as glycosaminoglycans or collagen) and/or biologically active agents.Type: GrantFiled: January 27, 2004Date of Patent: February 8, 2011Assignee: AngioDevice International GmbHInventors: Woonza M. Rhee, Frank A. DeLustro, Richard A. Berg
-
Publication number: 20090238857Abstract: The present invention discloses novel crosslinked biomaterial compositions which are prepared using hydrophobic polymers as a crosslinking agent. Preferred hydrophobic polymers are those that contain two or more reactive succinimidyl groups, including disuccinimidyl suberate, bix(sulfosuccinimidyl) suberate, and dithiobis(succinimidylpropionate). Crosslinked biomaterial compositions prepared using mixtures of hydrophobic and hydrophilic crosslinking agents are also disclosed. The compositions of the present invention can be used to prepare formed implants for use in a variety of medical applications.Type: ApplicationFiled: February 18, 2009Publication date: September 24, 2009Applicant: Angiotech Pharmaceuticals (US), Inc.Inventor: Woonza M. Rhee
-
Publication number: 20080187591Abstract: Compositions, methods, and kits are provided for sealing applications. Compositions are prepared by combining a first cross-linkable component with a second cross-linkable component to form a porous matrix having interstices, and combining the porous matrix with a hydrogel-forming component to fill at least some of the interstices. The compositions exhibit minimal swelling properties.Type: ApplicationFiled: August 1, 2007Publication date: August 7, 2008Applicants: Baxter International, Inc., Baxter Healthcare S.A.Inventors: Woonza M. Rhee, Cary J. Reich, A. Edward Osawa, Felix Vega
-
Patent number: 7176256Abstract: Crosslinked polymer compositions comprise a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple electrophilic groups. The first synthetic polymer is preferably a synthetic polypeptide or a polyethylene glycol that has been modified to contain multiple nucleophilic groups, such as primary amino (—NH2)or thiol (—SH) groups. The second synthetic polymer may be a hydrophilic or hydrophobic synthetic polymer which contains, or has been derivatized to contain, two or more electrophilic groups, such as succinimidyl groups. The compositions may further comprise other components, such as naturally occurring polysaccharides or proteins (such as glycosaminoglycans or collagen) and/or biologically active agents.Type: GrantFiled: June 21, 2004Date of Patent: February 13, 2007Assignee: Angiotech Pharmaceuticals (US), Inc.Inventors: Woonza M. Rhee, Frank A. DeLustro, Richard A. Berg
-
Patent number: 7151135Abstract: Provided are crosslinked polymer compositions that include a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple electrophilic groups. The first synthetic polymer is preferably a synthetic polypeptide or a polyethylene glycol that has been modified to contain multiple nucleophilic groups, such as primary amino (—NH2) or thiol (—SH) groups. The second synthetic polymer may be a hydrophilic or hydrophobic synthetic polymer, which contains or has been derivatized to contain, two or more electrophilic groups, such as succinimidyl groups. The compositions may further include other components, such as naturally occurring polysaccharides or proteins (such as glycosaminoglycans or collagen) and/or biologically active agents.Type: GrantFiled: March 10, 2005Date of Patent: December 19, 2006Assignee: Angiotech Pharmaceuticals (US), Inc.Inventors: Woonza M. Rhee, Frank A. DeLustro, Richard A. Berg
-
Patent number: 7129209Abstract: The present invention discloses novel crosslinked biomaterial compositions which are prepared using hydrophobic polymers as a crosslinking agent. Preferred hydrophobic polymers are those that contain two or more reactive succinimidyl groups, including disuccinimidyl suberate, bis(sulfosuccinimidyl)suberate, and dithiobis(succinimidyl)propionate. Crosslinked biomaterial compositions prepared using mixtures of hydrophobic and hydrophilic crosslinking agents are also disclosed. The compositions of the present invention can be used to prepare formed implants for use in a variety of medical applications.Type: GrantFiled: May 28, 2003Date of Patent: October 31, 2006Assignee: Angiotech Pharmaceuticlas (US), Inc.Inventor: Woonza M. Rhee